AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia

FEBS Journal

Volumn 281, Issue 4, 2014, Pages 1123-1131

  Fu, Lin ^a,b   Huang, Wenrong ^a   Jing, Yu ^a   Jiang, Mengmeng ^a,b   Zhao, Yu ^a   Shi, Jinglong ^a   Huang, Sai ^a   Xue, Xue ^a,b   Zhang, Qingyi ^a   Tang, Juying ^a   Dou, Liping ^a   Wang, Lili ^a   Nervi, Clara ^c   Li, Yonghui ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

acetylation; acute myeloid leukemia; AML1 ETO; early growth response gene l; P300

Indexed keywords

AML1-ETO FUSION PROTEIN, HUMAN; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; LEF1 PROTEIN, HUMAN; LYMPHOID ENHANCER FACTOR 1; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL PROLIFERATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROMOTER REGION;

ACETYLATION; APOPTOSIS; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EARLY GROWTH RESPONSE PROTEIN 1; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOID ENHANCER-BINDING FACTOR 1; ONCOGENE PROTEINS, FUSION; PROMOTER REGIONS, GENETIC; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894251525     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12673     Document Type: Article

References (28)

1. Peterson LF, &, Zhang DE, (2004) The 8;21 translocation in leukemogenesis. Oncogene 23, 4255-4262.
2. Dombret H, Preudhomme C, &, Boissel N, (2009) Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol 16, 92-97.
3. Baron V, Adamson ED, Calogero A, Ragona G, &, Mercola D, (2006) The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 13, 115-124.
4. Baek SJ, Kim JS, Moore SM, Lee SH, Martinez J, &, Eling TE, (2005) Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67, 356-364.
5. Heidel FH, Bullinger L, Arreba-Tutusaus P, Wang Z, Gaebel J, Hirt C, Niederwieser D, Lane SW, Dohner K, Vasioukhin V, et al,. (2013) The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med 210, 15-22.
6. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, &, Zhao K, (2009) Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019-1031.
7. Gao XN, Lin J, Ning QY, Gao L, Yao YS, Zhou JH, Li YH, Wang LL, &, Yu L, (2013) A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells. PLoS ONE 8, e55481.
8. Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C, et al,. (2013) Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 121, 499-509.
9. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, et al,. (2013) A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature 500, 93-97.
10. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, et al,. (2011) The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333, 765-769.
11. Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L, et al,. (2012) Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia. Blood 120, 3058-3068.
12. Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Dohner K, Feuring-Buske M, Braess J, Spiekermann K, Buchner T, et al,. (2012) High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 120, 2118-2126.
13. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, Lowenberg B, Delwel R, &, Valk PJ, (2009) Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131-134.
14. Jones JE, Wang L, Kropf PL, Duan R, &, Johnson DE, (2009) Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target. Leukemia 23, 1933-1935.
15. Turroni S, Tolomeo M, Mamone G, Picariello G, Giacomini E, Brigidi P, Roberti M, Grimaudo S, Pipitone RM, Di Cristina A, et al,. (2013) A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells. PLoS ONE 8, e57650.
16. Gibbs JD, Liebermann DA, &, Hoffman B, (2008) Leukemia suppressor function of Egr-1 is dependent on transforming oncogene. Leukemia 22, 1909-1916.
17. Gibbs JD, Liebermann DA, &, Hoffman B, (2008) Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene 27, 98-106.
18. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, Crispino JD, &, Le Beau MM, (2007) Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110, 719-726.
19. Liu P, Li J, Lu H, &, Xu B, (2009) Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. Leukemia Lymphoma 50, 109-113.
20. Ferraro B, Bepler G, Sharma S, Cantor A, &, Haura EB, (2005) EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 23, 1921-1926.
21. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, et al,. (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10, 155-167.
22. Vaissiere T, Sawan C, &, Herceg Z, (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659, 40-48.
23. Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, Kang HY, Yan GT, Wang LL, &, Yu L, (2011) MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 30, 3416-3428.
24. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, &, Zhang DE, (2001) Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 21, 5577-5590.
25. Lu Y, Xu YB, Yuan TT, Song MG, Lubbert M, Fliegauf M, &, Chen GQ, (2006) Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia 20, 987-993.
26. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al,. (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366, 1079-1089.
27. Ramirez-Herrick AM, Mullican SE, Sheehan AM, &, Conneely OM, (2011) Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood 117, 2681-2690.
28. Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson ED, &, Mercola D, (2005) Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 65, 5133-5143.